206 related articles for article (PubMed ID: 33164656)
1. Diabetes is a risk factor for high-dose methotrexate-associated AKI in lymphoma patients.
Wang Y; Wei L; Guan Y; Wang Q; Xie Q; Hao C
Ren Fail; 2020 Nov; 42(1):1111-1117. PubMed ID: 33164656
[TBL] [Abstract][Full Text] [Related]
2. Risk factors for high-dose methotrexate associated acute kidney injury in patients with hematological malignancies.
Amitai I; Rozovski U; El-Saleh R; Shimony S; Shepshelovich D; Rozen-Zvi B; Raanani P; Gafter-Gvili A; Gurion R
Hematol Oncol; 2020 Oct; 38(4):584-588. PubMed ID: 32506594
[TBL] [Abstract][Full Text] [Related]
3. Risk factors for high-dose methotrexate associated toxicities in patients with primary central nervous system lymphoma.
Sun K; Tao H; Ding T; Li Z; Qiu X; Zhong M; Wu Z
J Clin Pharm Ther; 2022 Dec; 47(12):2196-2204. PubMed ID: 36259502
[TBL] [Abstract][Full Text] [Related]
4. Outcomes Associated with Reducing the Urine Alkalinization Threshold in Patients Receiving High-Dose Methotrexate.
Drost SA; Wentzell JR; Giguère P; McLurg DL; Sabloff M; Kanji S; Nguyen TT
Pharmacotherapy; 2017 Jun; 37(6):684-691. PubMed ID: 28394433
[TBL] [Abstract][Full Text] [Related]
5. Preventing and Managing Toxicities of High-Dose Methotrexate.
Howard SC; McCormick J; Pui CH; Buddington RK; Harvey RD
Oncologist; 2016 Dec; 21(12):1471-1482. PubMed ID: 27496039
[TBL] [Abstract][Full Text] [Related]
6. Serum neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for predicting high dose methotrexate associated acute kidney injury in children with acute lymphoblastic leukemia.
Li H; Xu Q; Wang Y; Chen K; Li J
Cancer Chemother Pharmacol; 2020 Jan; 85(1):95-103. PubMed ID: 31676986
[TBL] [Abstract][Full Text] [Related]
7. Incidence and management of patients with methotrexate delayed elimination in the clinical practice: A Delphi study.
Gros L; Roldán A; Cabero-Martínez A; Domínguez-Pinilla N; de la Fuente A; González-Barca E; Tasso M; Torrent M; Gallardo E; Del Cerro I; Giró-Perafita A; Badia X
J Oncol Pharm Pract; 2023 Jun; 29(4):794-801. PubMed ID: 35147457
[TBL] [Abstract][Full Text] [Related]
8. Development and validation of a model to predict acute kidney injury following high-dose methotrexate in patients with lymphoma.
Rice ML; Barreto EF; Rule AD; Martin CE; Truong HL; Mara KC; Kashani KB; Thompson CA; Witzig TE; Barreto JN
Pharmacotherapy; 2024 Jan; 44(1):4-12. PubMed ID: 37926860
[TBL] [Abstract][Full Text] [Related]
9. Early, empiric high-dose leucovorin rescue in lymphoma patients treated with sequential doses of high-dose methotrexate.
Barreto JN; Peterson KT; Barreto EF; Mara KC; Dierkhising RA; Leung N; Witzig TE; Thompson CA
Support Care Cancer; 2021 Sep; 29(9):5293-5301. PubMed ID: 33661366
[TBL] [Abstract][Full Text] [Related]
10. The Application of
Wang L; Chen K; Xu Q
Biomed Res Int; 2020; 2020():3687134. PubMed ID: 33299868
[TBL] [Abstract][Full Text] [Related]
11. Statistical analysis of relation between plasma methotrexate concentration and toxicity in high-dose methotrexate therapy of childhood nonHodgkin lymphoma.
Tsurusawa M; Gosho M; Mori T; Mitsui T; Sunami S; Kobayashi R; Fukano R; Tanaka F; Fujita N; Inada H; Koh K; Takimoto T; Saito A; Fujimoto J; Nakazawa A; Horibe K;
Pediatr Blood Cancer; 2015 Feb; 62(2):279-284. PubMed ID: 25359701
[TBL] [Abstract][Full Text] [Related]
12. High-Dose Methotrexate in Patients With Lymphoma: Predictors of a Complicated Course.
O'Donoghue DF; Truong HL; Finnes HD; McDonald JS; May HP; Ansell SM; Bennani NN; Habermann TM; Inwards DJ; Johnston PB; Khurana A; Lin Y; Micallef IN; Nowakowski GS; Paludo J; Porrata LF; Thanarajasingam G; Thompson CA; Villasboas JC; Wang Y; Witzig TE; Leung N
JCO Oncol Pract; 2022 Dec; 18(12):e1908-e1917. PubMed ID: 36240468
[TBL] [Abstract][Full Text] [Related]
13. Risk factors for acute kidney injury after high-dose methotrexate therapy: a single-center study and narrative review.
Liang CA; Su YC; Lin SJ; Tsai TH
Eur J Clin Pharmacol; 2023 Jun; 79(6):789-800. PubMed ID: 37060460
[TBL] [Abstract][Full Text] [Related]
14. A pharmacologically-based approach to high dose methotrexate administration to investigate nephrotoxicity and acute kidney injury biomarkers in children and adolescents with newly diagnosed osteosarcoma.
Fox E; Busch C; DeBernardo A; Segers B; Gottschalk J; Womer R; Balamuth N; Bagatell R; Balis F
Cancer Chemother Pharmacol; 2021 Jun; 87(6):807-815. PubMed ID: 33677616
[TBL] [Abstract][Full Text] [Related]
15. Lack of drug interaction between levetiracetam and high-dose methotrexate in patients with lymphoma.
DeFino CE; Barreto JN; Pawlenty AG; Ruff MW; Carabenciov ID; Mara KC; Thompson CA
Pharmacotherapy; 2021 May; 41(5):430-439. PubMed ID: 33655525
[TBL] [Abstract][Full Text] [Related]
16. High-dose methotrexate toxicity in elderly patients with primary central nervous system lymphoma.
Jahnke K; Korfel A; Martus P; Weller M; Herrlinger U; Schmittel A; Fischer L; Thiel E;
Ann Oncol; 2005 Mar; 16(3):445-9. PubMed ID: 15653703
[TBL] [Abstract][Full Text] [Related]
17. High incidence of methotrexate associated renal toxicity in patients with lymphoma: a retrospective analysis.
May J; Carson KR; Butler S; Liu W; Bartlett NL; Wagner-Johnston ND
Leuk Lymphoma; 2014 Jun; 55(6):1345-9. PubMed ID: 24004183
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of incidence and risk factors for high-dose methotrexate-induced nephrotoxicity.
Wiczer T; Dotson E; Tuten A; Phillips G; Maddocks K
J Oncol Pharm Pract; 2016 Jun; 22(3):430-6. PubMed ID: 26152702
[TBL] [Abstract][Full Text] [Related]
19. Delayed elimination of high-dose methotrexate and use of carboxypeptidase G2 in pediatric patients during treatment for acute lymphoblastic leukemia.
Svahn T; Mellgren K; Harila-Saari A; Åsberg A; Kanerva J; Jónsson Ó; Vaitkeviciene G; Stamm Mikkelssen T; Schmiegelow K; Heldrup J
Pediatr Blood Cancer; 2017 Jul; 64(7):. PubMed ID: 27966809
[TBL] [Abstract][Full Text] [Related]
20. Outpatient administration of high-dose methotrexate in adults without drug monitoring - a case-control study of risk factors for acute kidney injury.
Alves C; Pereira J; Rego EM; Rocha V; Silva WF
Hematol Transfus Cell Ther; 2023 Dec; ():. PubMed ID: 38233304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]